Antagonizing Bcl-2 Family Members Sensitizes Neuroblastoma and Ewing’s Sarcoma to an Inhibitor of Glutamine Metabolism
Open Access
- 23 January 2015
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (1) , e0116998
Abstract
Neuroblastomas (NBL) and Ewing’s sarcomas (EWS) together cause 18% of all pediatric cancer deaths. Though there is growing interest in targeting the dysregulated metabolism of cancer as a therapeutic strategy, this approach has not been fully examined in NBL and EWS. In this study, we first tested a panel of metabolic inhibitors and identified the glutamine antagonist 6-diazo-5-oxo-L-norleucine (DON) as the most potent chemotherapeutic across all NBL and EWS cell lines tested. Myc, a master regulator of metabolism, is commonly overexpressed in both of these pediatric malignancies and recent studies have established that Myc causes cancer cells to become “addicted” to glutamine. We found DON strongly inhibited tumor growth of multiple tumor lines in mouse xenograft models. In vitro, inhibition of caspases partially reversed the effects of DON in high Myc expressing cell lines, but not in low Myc expressing lines. We further showed that induction of apoptosis by DON in Myc-overexpressing cancers is via the pro-apoptotic factor Bax. To relieve inhibition of Bax, we tested DON in combination with the Bcl-2 family antagonist navitoclax (ABT-263). In vitro, this combination caused an increase in DON activity across the entire panel of cell lines tested, with synergistic effects in two of the N-Myc amplified neuroblastoma cell lines. Our study supports targeting glutamine metabolism to treat Myc overexpressing cancers, such as NBL and EWS, particularly in combination with Bcl-2 family antagonists.Keywords
This publication has 32 references indexed in Scilit:
- ATF4 Regulates MYC-Mediated Neuroblastoma Cell Death upon Glutamine DeprivationCancer Cell, 2012
- Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYCProceedings of the National Academy of Sciences, 2012
- Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not AnticipateCancer Cell, 2012
- Glucose-Independent Glutamine Metabolism via TCA Cycling for Proliferation and Survival in B CellsCell Metabolism, 2012
- Glutamine addiction: a new therapeutic target in cancerTrends in Biochemical Sciences, 2010
- Q's next: the diverse functions of glutamine in metabolism, cell biology and cancerOncogene, 2009
- c-Myc activates multiple metabolic networks to generate substrates for cell-cycle entryOncogene, 2009
- International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology CommitteeBritish Journal of Cancer, 2009
- Brick by brick: metabolism and tumor cell growthCurrent Opinion in Genetics & Development, 2008
- Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesisProceedings of the National Academy of Sciences, 2007